Avalyn Pharma launches $300M IPO, selling 16.5 million shares at $18 each
read at Endpoints ↗DealNeutral
Avalyn Pharma, a Boston-based biotech, announced an initial public offering that aims to raise roughly $300 million.
The company will sell more than 16.5 million shares at $18 per share and is set to begin trading on Nasdaq under the ticker AVLN on Thursday.
The financing bolsters Avalyn's capital as it advances its development pipeline and positions the firm for future growth.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Avalyn's upsized IPO; Alector ends another study in GSK partnership”
read at Endpoints ↗78 words · retrieved Apr 30
comments(0)
5-min edit window · permanent after that